Connect
MJA
MJA

Implementing US-style anti-fraud laws in the Australian pharmaceutical and health care industries

Thomas A Faunce, Gregor Urbas and Lesley Skillen
Med J Aust 2011; 194 (9): 474-478.

Summary

  • Thomas A Faunce1,2
  • Gregor Urbas3
  • Lesley Skillen4

  • 1 College of Medicine, Biology and Environment, Australian National University, Canberra, ACT.
  • 2 Australian Research Council, Canberra, ACT.
  • 3 College of Law, Australian National University, Canberra, ACT.
  • 4 Getnick and Getnick LLP, New York, NY, USA.

Correspondence: Fauncet@law.anu.edu.au

Competing interests:

Thomas Faunce and Gregor Urbas are Chief Investigators and Lesley Skillen is a Partner Investigator on an Australian Research Council (ARC) Discovery Grant in this area. The ARC was not involved in the writing of this paper. Lesley Skillen is a senior partner with Getnick and Getnick LLP, a US firm specialising in anti-false claims litigation.

  • 1. Australian Government Department of Innovation, Industry, Science and Research. Australian pharmaceuticals industry fact sheet. 26 Oct 2010. Canberra: Commonwealth of Australia, 2010.
  • 2. Australian Institute of Health and Welfare. Health expenditure Australia 2007–08. Canberra: AIHW, 2009. (Cat No. HWE 46; Health and Welfare Expenditure Series No. 37.)
  • 3. Business Monitor International. Australia pharmaceuticals and healthcare report Q4 2010. London: BMI, 2010.
  • 4. World Health Organization. World health statistics 2010. Geneva: WHO, 2010. http://www.who.int/whosis/whostat/EN_WHSIO_Full.pdf (accessed Apr 2011).
  • 5. Kesselheim AS, Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Intern Med 2008; 149: 342-349.
  • 6. Faunce TA, Townsend R McEwan A. The Vioxx pharmaceutical scandal. J Law Med 2010; 18: 38-49.
  • 7. KPMG Forensic. Fraud and misconduct survey 2010, Australia and New Zealand. KPMG, 2010.
  • 8. Medicare Australia. Fraud. http://www.medicareaustralia.gov.au/provider/business/audits/fraud.jsp (accessed Nov 2010).
  • 9. Vitamin firm price-fixers face record court fines [editorial]. Australian Financial Review 2000; 6 Dec.
  • 10. US ex rel Kelly v The Boeing Company [1993] 9 F.3d 743.
  • 11. Boese JT, Anderson D. Fundamentals of the civil False Claims Act and qui tam enforcement. Proceedings of the Eighth Annual National Institute on the Civil False Claims Act and Qui Tam Enforcement; 2010 Jun 2-4; Washington, DC.
  • 12. Getnick NV, Skillen LA. City False Claims Act: next chapter in anti-fraud crusade. N Y Law J 2005; 13 Oct: 4-12.
  • 13. US Department of Justice. Department of Justice recovers $3 billion in false claims cases in fiscal year 2010 [media release]. 22 Nov 2010. http://www.justice.gov/opa/pr/2010/November/10-civ-1335.html (accessed Nov 2010).
  • 14. Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med 2009; 360: 1557-1566.
  • 15. Cook County v US ex rel Chandler (2003) 123 S Ct 1239; 30 TAF QR 1.
  • 16. Kesselheim AS, Studdert DM. Whistle-blowers’ experiences in fraud litigation against pharmaceutical companies. N Engl J Med 2010; 362: 1832-1839.
  • 17. United States v Neifert-White (1968) 390 US 228: 232.
  • 18. Meyer JA. Fighting Medicare fraud: more bang for the federal buck. Prepared for Taxpayers Against Fraud Education Fund. Jul 2006. http://www.taf.org/publications.htm (accessed Nov 2010).
  • 19. Stewart BR, Sunstein CR. Public programs and private rights. Harvard Law Rev 1982; 95: 1193.
  • 20. Blomquist FR. Rethinking the citizen as prosecutor model of environmental enforcement under the Clean Water Act: some overlooked problems of outcome-independent values. Georgia Law Rev 1988; 22: 337-338.
  • 21. US ex rel Duxbury v Ortho Biotech Products LP [2009] WL 2450716 (1st Circuit Court of Appeals, 12 Aug 2009).
  • 22. Faunce TA, Bolsin SNC. Three Australian whistleblowing sagas: lessons for internal and external regulation. Med J Aust 2004; 181: 44-47. <MJA full text>
  • 23. House of Representatives Standing Committee on Legal and Constitutional Affairs. Fair shares for all: insider trading in Australia. Canberra: Australian Government Publishing Service, 1989.
  • 24. House of Representatives Standing Committee on Legal and Constitutional Affairs. Whistleblower protection: a comprehensive scheme for the Commonwealth public sector. Canberra: Commonwealth of Australia, 2009. http://www.aph.gov.au/house/committee/laca/whistleblowing/report/fullreport.pdf (accessed Apr 2011).
  • 25. Standing Committee of Attorneys General. Litigation funding in Australia. Canberra: Commonwealth of Australia, 2005.
  • 26. Phelps v Western Mining Corporation Ltd (1978) 20 ALR 183.
  • 27. Truth About Motorways Pty Ltd v Macquarie Infrastructure Investment Management Ltd (2000) 200 CLR 591.
  • 28. Commonwealth Bank of Australia v Gargan (2004) 140 FCR 1.
  • 29. Blatt RL, Hammesfahr RW, Nugent LS. Punitive damages: a state-by-state guide to law and practice. Eagan, Minn: West, 2003.
  • 30. Law Council of Australia. Second submission to the Negligence Review Panel on the review of the law of negligence. 2 Sep 2002. Canberra: LCA, 2002.
  • 31. Tomasic R, Pentony B. Insider trading in Australia. Part I: regulation and law enforcement. Canberra: Corporate Law Research Group, 1988. http://www.criminologyresearchcouncil.gov.au/reports/7-87-1.pdf (accessed Nov 2010).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.